Last reviewed · How we verify
Arm A: FOLFIRI or FOLFOX + Bevacizumab
Arm A: FOLFIRI or FOLFOX + Bevacizumab is a Chemotherapy combination + VEGF inhibitor Small molecule drug developed by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS. It is currently in Phase 3 development for Metastatic colorectal cancer, Advanced colorectal cancer. Also known as: Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB.
FOLFIRI or FOLFOX chemotherapy regimens combined with bevacizumab inhibit tumor cell division and angiogenesis to treat colorectal cancer.
FOLFIRI or FOLFOX chemotherapy regimens combined with bevacizumab inhibit tumor cell division and angiogenesis to treat colorectal cancer. Used for Metastatic colorectal cancer, Advanced colorectal cancer.
At a glance
| Generic name | Arm A: FOLFIRI or FOLFOX + Bevacizumab |
|---|---|
| Also known as | Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB |
| Sponsor | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
| Drug class | Chemotherapy combination + VEGF inhibitor |
| Target | DNA (chemotherapy); VEGF (bevacizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFIRI (fluorouracil, leucovorin, irinotecan) and FOLFOX (fluorouracil, leucovorin, oxaliplatin) are cytotoxic chemotherapy combinations that damage DNA and inhibit cell proliferation. Bevacizumab is a monoclonal antibody targeting VEGF that blocks tumor angiogenesis, preventing new blood vessel formation and starving tumors of nutrients and oxygen.
Approved indications
- Metastatic colorectal cancer
- Advanced colorectal cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea and vomiting
- Fatigue
- Peripheral neuropathy
- Hypertension
- Bleeding
- Thrombosis
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers (PHASE1)
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (PHASE1)
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis (EARLY_PHASE1)
- Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer (PHASE3)
- Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arm A: FOLFIRI or FOLFOX + Bevacizumab CI brief — competitive landscape report
- Arm A: FOLFIRI or FOLFOX + Bevacizumab updates RSS · CI watch RSS
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS portfolio CI
Frequently asked questions about Arm A: FOLFIRI or FOLFOX + Bevacizumab
What is Arm A: FOLFIRI or FOLFOX + Bevacizumab?
How does Arm A: FOLFIRI or FOLFOX + Bevacizumab work?
What is Arm A: FOLFIRI or FOLFOX + Bevacizumab used for?
Who makes Arm A: FOLFIRI or FOLFOX + Bevacizumab?
Is Arm A: FOLFIRI or FOLFOX + Bevacizumab also known as anything else?
What drug class is Arm A: FOLFIRI or FOLFOX + Bevacizumab in?
What development phase is Arm A: FOLFIRI or FOLFOX + Bevacizumab in?
What are the side effects of Arm A: FOLFIRI or FOLFOX + Bevacizumab?
What does Arm A: FOLFIRI or FOLFOX + Bevacizumab target?
Related
- Drug class: All Chemotherapy combination + VEGF inhibitor drugs
- Target: All drugs targeting DNA (chemotherapy); VEGF (bevacizumab)
- Manufacturer: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
- Indication: Drugs for Advanced colorectal cancer
- Also known as: Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB
- Compare: Arm A: FOLFIRI or FOLFOX + Bevacizumab vs similar drugs
- Pricing: Arm A: FOLFIRI or FOLFOX + Bevacizumab cost, discount & access